F8 and hemophilia: The objective was to evaluate the efficacy of emicizumab, as compared with previous FVIII concentrates, by measuring changes in several endpoints: ABR, annual joint bleed rate, annual target joint bleed rate, joint health using the Hemophilia Joint Health Score (HJHS), functional activity through the Functional Independence Score in Hemophilia (FISH), and QoL via the European Quality of Life 5‐Dimensions 5‐levels (EQ‐5D‐5L) questionnaire and visual analog scale (EQ‐VAS).